RE: RE: RE: NEWS RELEASEI think it is safe to say cheap bidding has been, and is still there, and with everyones knowledge that value increases dramatically,including a more favorable possible partnership can be had with phase test results. Picking the target cancer for tests is critical and will also determine interest from more specific bidders. It all looks good in my opinion and don't forget the Toronto group sees this reported firm course and therefore more funding interest should be avail. As can be evidenced from other similiar situations, once phase 1 and /or phase 2 gets underway, investors flock towards the co. and want to invest before the results are in for obvious reason. IMHO.